MITOMYCIN: EFFECTS ON LARYNGEAL AND TRACHEAL STENOSIS, BENEFITS, AND COMPLICATIONS

REZA RAHBAR, DMD, MD
STANLEY M. SHAPSHAY, MD
GERALD B. HEALY, MD
BOSTON, MASSACHUSETTS

The management of laryngeal and tracheal stenosis continues to challenge us, despite advances in surgical techniques and better understanding of the wound healing process. Injury to the airway mucosa is the inciting event, regardless of the cause of the stenosis. Mitomycin-C is an antineoplastic antibiotic that acts as an alkylating agent by inhibiting DNA and protein synthesis. It can inhibit cell division, protein synthesis, and fibroblast proliferation. Topical application of mitomycin-C (0.4 mg/ml) was used as an adjuvant treatment in the endoscopic laser management of laryngeal and tracheal stenosis in 15 patients. Fourteen patients (93%) have shown improvement of their airway and resolution of their preoperative symptoms. After a mean follow-up of 18 months, no complication was noted with regard to the application of mitomycin-C. This study gives promising findings on the efficacy and safety of mitomycin-C as an adjuvant treatment in the management of selected cases of laryngeal and tracheal stenosis.

KEY WORDS — endoscopic surgery, laryngeal stenosis, laser surgery, mitomycin-C, subglottic stenosis, tracheal stenosis.

INTRODUCTION

Treatment of laryngeal and tracheal stenosis remains one of the most difficult and perplexing problems in the area of head and neck surgery. Scar formation and restenosis remains the main cause of failure in the surgical management of airway stenosis. Modulation of the wound healing process to prevent excessive scar formation can play a major role in improving the success rate and decreasing the need for further surgery.

Mitomycin-C is an antiproliferative agent that can inhibit fibroblast proliferation and activity. It has been successfully used as an adjuvant treatment in a number of ophthalmologic procedures to decrease scar formation and restenosis.

A multicenter prospective clinical trial was undertaken to evaluate the efficacy and safety of the topical application of mitomycin-C in the prevention and treatment of airway stenosis. Mitomycin-C was used as an adjuvant treatment in the endoscopic laser management of laryngeal or tracheal stenosis in 15 patients. The preliminary results of some of these patients have been reported.!

MATERIALS AND METHODS

Fifteen patients underwent endoscopic laser management of laryngeal or tracheal stenosis and the topical application of mitomycin-C at New England Medical Center and The Children's Hospital, Boston, between January 1998 and December 1999. There were 8 male patients and 7 female patients. The patients' ages ranged from 2 to 78 years (mean, 32 years). The patients presented with preoperative symptoms of dyspnea interfering with routine daily activity, poor voice quality and vocal fatigue, and/or the inability to cap their tracheotomy tube. Included were 3 cases of glottic stenosis, 10 cases of subglottic stenosis, and 2 cases of tracheal stenosis (see Table).!

Glottic Stenosis. One patient (No. 1) presented with a congenital anterior glottic web. Two patients (Nos. 2 and 3) were treated with posterior glottic stenosis and arytenoid fixation: 1 patient had undergone a tracheotomy and laryngofissure for repair of a blunt laryngeal trauma, and the other had undergone a tracheotomy and partial arytenoidectomy for bilateral vocal cord paralysis caused by a brain stem infarct. Only patient 3 was tracheotomy-dependent at the time of our evaluation, with an inability to cap the tracheotomy tube and poor voice quality.

Subglottic Stenosis. Three patients (Nos. 5, 11, and 13) presented with subglottic stenosis due to prolonged intubation because of cardiac surgery, pneumonia, and tracheal infarct, respectively. One patient (No. 4) presented with restenosis after a laryngotracheal reconstruction for a congenital subglottic stenosis (grade IV). No cause could be identified in
<table>
<thead>
<tr>
<th>Pt No.</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Location of Stenosis</th>
<th>Tracheotomy-Dependent</th>
<th>No. of Procedures</th>
<th>Initial Airway Stenosis</th>
<th>Thickness (mm)</th>
<th>Current Airway Stenosis</th>
<th>Initial Symptoms</th>
<th>Current Status</th>
<th>Follow-up (mo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>5</td>
<td>Glottic</td>
<td>Congenital web</td>
<td>No</td>
<td>2</td>
<td>60%</td>
<td>4</td>
<td>20%</td>
<td>B</td>
<td>F</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>14</td>
<td>Glottic</td>
<td>Laryngeal trauma</td>
<td>No</td>
<td>1</td>
<td>4-mm opening</td>
<td>7-mm opening</td>
<td>A, B</td>
<td>F</td>
<td>23</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>78</td>
<td>Glottic</td>
<td>Bilateral vocal cord</td>
<td>Yes</td>
<td>3</td>
<td>2-mm opening</td>
<td>5-mm opening</td>
<td>B, C</td>
<td>D, E</td>
<td>25</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>14</td>
<td>Subglottic*</td>
<td>Congenital</td>
<td>Yes</td>
<td>1</td>
<td>80%</td>
<td>4</td>
<td>20%</td>
<td>B, C</td>
<td>D, E</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>17</td>
<td>Subglottic</td>
<td>Prolonged intubation</td>
<td>No</td>
<td>1</td>
<td>80%</td>
<td>5</td>
<td>30%</td>
<td>A, B</td>
<td>F*</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>33</td>
<td>Subglottic*</td>
<td>Idiopathic subglottic stenosis</td>
<td>No</td>
<td>1</td>
<td>80%</td>
<td>15</td>
<td>20%</td>
<td>A, B</td>
<td>F</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>38</td>
<td>Subglottic</td>
<td>Idiopathic subglottic stenosis</td>
<td>No</td>
<td>1</td>
<td>50%</td>
<td>12</td>
<td>20%</td>
<td>A, B</td>
<td>F</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>40</td>
<td>Subglottic*</td>
<td>Idiopathic subglottic stenosis</td>
<td>No</td>
<td>1</td>
<td>80%</td>
<td>4</td>
<td>20%</td>
<td>A, B</td>
<td>F</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>42</td>
<td>Subglottic*</td>
<td>Idiopathic subglottic stenosis</td>
<td>No</td>
<td>1</td>
<td>50%</td>
<td>7</td>
<td>10%</td>
<td>A, B</td>
<td>F</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>45</td>
<td>Subglottic*</td>
<td>Idiopathic subglottic stenosis</td>
<td>No</td>
<td>2</td>
<td>70%</td>
<td>10</td>
<td>10%</td>
<td>A, B</td>
<td>F</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>48</td>
<td>Subglottic</td>
<td>Prolonged intubation</td>
<td>Yes</td>
<td>2</td>
<td>95%</td>
<td>4</td>
<td>40%</td>
<td>A, B, C</td>
<td>D, E</td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>53</td>
<td>Subglottic</td>
<td>Wegener’s granulomatosis</td>
<td>No</td>
<td>1</td>
<td>50%</td>
<td>5</td>
<td>10%</td>
<td>A</td>
<td>F</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>56</td>
<td>Subglottic</td>
<td>Prolonged intubation</td>
<td>No</td>
<td>2</td>
<td>70%</td>
<td>5</td>
<td>30%</td>
<td>A, B</td>
<td>F</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>2</td>
<td>Tracheal</td>
<td>Prolonged intubation</td>
<td>No</td>
<td>1</td>
<td>70%</td>
<td>5</td>
<td>60%</td>
<td>A</td>
<td>F</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>5</td>
<td>Tracheal</td>
<td>Congenital stenosis</td>
<td>No</td>
<td>2</td>
<td>70%</td>
<td>3</td>
<td>10%</td>
<td>A, B</td>
<td>F</td>
</tr>
</tbody>
</table>

A = dyspnea on routine daily activity; B = poor voice quality and vocal fatigue; C = inability to cap tracheotomy tube; D = improved voice quality; E = ability to cap tracheotomy tube during day; F = resolution of preoperative symptoms.

*Circumferential scarring.

5 cases (patients 6 through 10), which were classified as idiopathic subglottic stenosis. Wegener’s granulomatosis was the cause of subglottic stenosis in 1 patient (No. 12). Only 2 patients from this group (Nos. 4 and 11) were tracheotomy-dependent, with an inability to cap the tracheotomy tube and poor voice quality.

Tracheal Stenosis. One patient (No. 14), with a history of trisomy 21, presented with tracheal stenosis after prolonged intubation because of cardiac and pulmonary status. A second patient (No. 15) presented with tracheal stenosis after laryngotracheal reconstruction for a congenital subglottic and tracheal stenosis.

All patients underwent endoscopic examination and treatment under inhalational general anesthesia provided via a tracheotomy tube, when present, or intravenous anesthesia and Venturi jet ventilation. The airway size and length of stenosis were measured with an open tube ventilating bronchoscope or an endotracheal tube through a laryngoscope. Surgical exposure was obtained by placing the tip of a laryngoscope (Dedo, Healy-Jako, or anterior commissure scope) through the vocal cords for subglottic and tracheal stenosis. The laryngoscope was suspended from a Boston University suspension apparatus, and an operating microscope was used at 16× magnification for all cases. The CO2 laser at a power setting of 4 to 6 W (time, 0.1 to 0.3 second), in a
superpulsed mode (0.25- to 0.3-mm spot size) was used to make radial incisions through the subglottic or tracheal stenosis (Fig 1). Ventilating open tube bronchoscopes were then used for dilation of the stenotic segment. The radial incisions in subglottic or tracheal stenotic areas served to guide the dilating forces in a controlled manner to preserve viable epithelium within the incision. A similar laser setting was used for excision of glottic stenosis (Fig 2). Thereafter, a 10-mm cottonoid sponge was soaked with mitomycin-C 0.4 mg/mL and topically applied to the surgical site for 4 minutes. Then the area was irrigated with 20 to 30 mL of normal saline solution. All patients were observed for a minimum of 24 hours after the procedure. Success was defined as an improvement in the size of the airway and elimination of the preoperative symptoms.

RESULTS

A total of 22 procedures were performed in 13 patients (average, 1.5 procedures): 9 patients had 1 procedure each, 5 patients had 2 procedures each, and 1 patient had 3 procedures. The follow-up ranged from 6 to 29 months, with an average of 18 months. Open tube bronchoscopes and/or endotracheal tubes were used for the measurement of the postoperative length and degree of stenosis under general anesthesia, or the measurements were made with fiberoptic laryngoscopy and still photographs taken by means of a 70° rigid telescope under topical anesthesia. Fourteen patients (93%) showed an improvement in the degree of airway stenosis and resolution of their preoperative symptoms (see Table). The postoperative length and degree of subglottic or tracheal stenosis could only be measured in patients who underwent general anesthesia because of the need for further surgery. There was no significant improvement noted in the length of the stenosis.

Glottic Stenosis. A total of 6 procedures were performed in 3 patients. Before operation, 1 patient demonstrated a 60% stenosis, and 2 patients had posterior airway openings of 4 and 2 mm, respectively, compared to a postoperative stenosis of 20% and airway openings of 7 and 5 mm, respectively. Two patients were completely asymptomatic with regard to their preoperative symptoms. One patient was tracheotomy-dependent, was unable to cap the tracheotomy tube, and had poor voice quality. Currently, the tracheotomy tube is capped during the day without dyspnea on exertion, and the patient has good voice quality.

---


The patient has not been decannulated because of his general medical condition following a brain stem infarct.

Subglottic Stenosis. A total of 13 procedures were performed in 10 patients. The preoperative stenosis ranged from 50% to 95% (mean, 71%), and the postoperative stenosis ranged from 10% to 40% (mean, 21%). The length of the stenosis ranged from 4 to 15 mm (average, 7 mm). Three patients had a length of stenosis equal to or greater than 1 cm. Before operation, 9 patients had moderate dyspnea with routine daily activity; currently, they are all free of symptoms. Two patients were tracheotomy-dependent before the procedure, with an inability to cap the tracheotomy tube and poor voice quality. Currently, both patients tolerate capping the tracheotomy tubes during the day and have improved voice quality. One patient (No. 11) has not been decannulated because of his general medical condition (diabetes and recurrent pneumonia); the second patient (No. 4) is scheduled for decannulation in the near future.

Tracheal Stenosis: A total of 3 procedures were performed in 2 patients. The preoperative degree of stenosis was 70% in both patients; the stenoses were 3 and 5 mm long, respectively. One patient (No. 15) is asymptomatic with 10% airway obstruction. The second patient (No. 14), whose history is significant for trismus 21, tetralogy of Fallot, and pulmonary arteriovenous malformation, presented with restenosis and underwent tracheotomy because of worsening of his pulmonary and cardiac status.

DISCUSSION

The management of laryngeal and tracheal stenosis remains difficult, requiring accurate diagnosis and a proper treatment plan. The goal of any treatment is the restoration of an adequate airway, the provision of a competent larynx for protection against aspiration, and the achievement of a satisfactory voice. The first decision is whether an open surgical technique is necessary, or whether an endoscopic approach is adequate. Factors such as 1) age, 2) general medical condition, 3) cause, location, degree, length, and consistency of stenosis, and 4) previous treatment should be considered. There is still controversy with regard to the optimum approach in the treatment of laryngeal and tracheal stenosis.

Endoscopic management of laryngeal and tracheal lesions has undergone tremendous advancement in the past 2 decades. The development of microlaryngoscopy and adaptation of the binocular operating microscope, the introduction of endolaryngeal CO₂ laser surgery, the coupling of an endoscopic adapter to a ventilating bronchoscope, and the development of the microspot manipulator allow microprecision and hemostatic ability, which were lacking with the standard instrumentation of conventional endoscopic techniques. Multiple endoscopic techniques have been described: microcurettement, dilatation with local and systemic steroids, and cryosurgery have all had some success. Strong and Jakob⁶ first published their experience with endoscopic CO₂ laser management of laryngeal stenosis in 1972. The CO₂ laser appears to be the most effective means for treating mild to moderate stenosis of the larynx and trachea endoscopically.⁹,¹²

With the advancements in endoscopic surgical technique and a better understanding of the wound healing process, and even the introduction of mucosa-preserving laser surgery such as the microtrapdoor flap technique (Dedo and Sooy¹³) and radial incision and dilation (Shapshay et al.), there is still a high degree of scar formation and restenosis. A review of the literature reveals a wide range of success for endoscopic management of laryngeal and tracheal stenosis: Strong et al.¹⁴ 50% success; Andrews and Horowitz,¹⁵ 66% success; Simpson et al.,¹⁶ 44% success; Carruth,¹⁷ 50% success; Shapshay and Simpson,³ 40% success; and Ossoff et al.,¹⁸ 57% success. Although there are fundamental differences between these studies (definition of success; location; severity, and type of stenosis; length of follow-up), restenosis and scar formation remains the primary cause of failure.

Regardless of the surgical techniques, there is further injury to the airway mucosa that leads to fibroblast proliferation and collagen formation, which are the key to scar formation. Modulation of the wound healing response to prevent excessive scar formation can play a major role in increasing the success of surgical treatment and reducing the need for further surgery. In the past decade, the role of growth factors and fibrogenic peptides in the regulation and modulation of wound healing leading to fibrosis and scar formation has been reported.¹⁹,²¹ Pharmacological agents such as 5-fluorouracil and β-aminopropionitrile (BAPN) have been shown to inhibit the development of collagen cross-linking, thus minimizing scar formation.²²,²³

Kunitomo and Mori²⁴ presented the first clinical use of mitomycin-C in the prevention and treatment of scar formation in pterygium surgery. Later, Chen,²⁵ Palmer,²⁶ and Bergstrom et al.²⁷ reported its use for prevention of restenosis in glaucoma surgery.

Mitomycin-C is an antibiotic produced by Streptomyces caesporus. It is referred to as mitomycin-C to differentiate both antineoplastic agents: inhibit RN and also acts as a fibroblast action.

The exact nature of mitomycin-C is still under investigation. Mitomycin-C decreases the vascularity and mitotic index of the surface epithelium of the pterygium, reduces inflammation, and decreases pterygium recurrence rate. Mitomycin-C is believed to inhibit the proliferation of pterygium fibroblasts and collagen production, which may be responsible for the reduced recurrence rate of pterygium.

Mitomycin-C is a potent inhibitor of angiogenesis, which is responsible for the growth of new blood vessels in the pterygium. It is believed to inhibit the proliferation of pterygium fibroblasts and collagen production, which may be responsible for the reduced recurrence rate of pterygium.

to differentiate it from mitomycins A and B. It has both antimetabolic and antiproliferative properties. Its antimetabolic activity is similar to that of the alkylating agents, causing cross-linking of DNA and inhibiting RNA and protein synthesis. Mitomycin-C also acts as an antiproliferative agent that can inhibit fibroblast activity and suppress fibrosis and scar formation.

The exact mechanism by which mitomycin-C exerts an antifibroblast activity is unknown. There is evidence to suggest that the reduction of fibroblast activity may be mediated by apoptosis, which is a gene-directed process causing cell death. Apoptotic cells display a characteristic morphology that includes condensation of the nucleus and cytoplasm, nuclear fragmentation, and cytoplasmic blebbing with an intact cell membrane. Lee et al. showed that mitomycin has antifibroblastic properties in vivo. Khaw et al. showed that in vitro, a single application of mitomycin could inhibit fibroblast proliferation. Mitomycin has been successfully used for prevention of stenosis in glaucoma surgery, dacryocystorhinostomy, optic nerve sheath meningioma, and pterygium recurrence. The fibroblast population and collagen formation are substantially increased during the wound healing response that follows a mucosal insult such as a surgical procedure. The rationale of the use of mitomycin-C is to inhibit fibroblast proliferation during the postoperative phase without damaging the mucosal and epithelial growth.

Historically, endoscopic management of patients with circumferential scarring, a vertical scar greater than 1 cm, posterior scarring with arytenoid fixation, and loss of cartilaginous support had a high failure rate. We have presented 15 patients with laryngeal and tracheal stenosis. A group of these patients have characteristics of airway stenosis that falls into the category of high failure rate based on historical experience: 6 patients with circumferential stenosis of the subglottic area; 2 patients with posterior glottic stenosis and arytenoid fixation; and 3 patients with length of subglottic stenosis greater than 1 cm. The endoscopic management of airway stenosis has produced a success rate of 40% to 68%, as reported by experienced investigators, with most results being closer to 50%. We have defined success as clinical improvement of the degree of stenosis and the resolution of preoperative symptoms. We have shown improvement of the size of the airway and resolution of preoperative symptoms in 14 patients (93% success rate), without any complications, with a mean follow-up of 18 months. Three of our patients were tracheotomy-dependent at the time of our evaluation. They have shown improvement of their airway, allowing capping of their tracheotomy tube during the day, and improvement of their voice quality. Two of these patients have not been decannulated because of their general medical condition, and 1 is scheduled for decannulation in the near future.

Our results demonstrate that the topical application of mitomycin-C can be beneficial in the modulation of wound healing and in decreasing scar formation in the treatment of airway stenosis. Our study is the first to describe the use of mitomycin-C as an adjuvant treatment in the endoscopic management of laryngeal and tracheal stenosis in both pediatric and adult populations. Further research and randomized prospective clinical trials are needed to determine the most effective concentration and time of exposure of mitomycin-C, and the difference in efficacy and safety between single and multiple applications.

CONCLUSION

Treatment of laryngeal and tracheal stenosis remains a therapeutic challenge. Different surgical techniques have been proposed, and no single approach has proven satisfactory for all cases. With the advances in the surgical techniques and the recognition of the importance of mucosal preservation, the potential for endoscopic surgical techniques has expanded. Restenosis and scar formation remain the main cause of failure in these cases. This study reveals promising results in terms of the efficacy and safety of mitomycin-C as an adjuvant method for the management of laryngeal and tracheal stenosis.

REFERENCES

Rahbar et al. Mitomycin
28. Desmitubiere A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995;146:566-

LOCAL FOR E

Although recurrences, re operati
Their charts w
TINOMO, 21 (mo
total laryngec
had no curative
treatment met
of recurrent di
carrier in th

KEY WO

For early glottic carcinoma rates have be
has emerged early glottic 20 years.6-11 Open surgeries been found to postoperatively after open procedures. The periope
alization is not disturbed frequently location.13,15 As
time-consuming cost-effectivity, both for confirm patients with
to UICC anc

From the D
Uhrmacher
Presented at
 CORRESP